Global Diabetic Neuropathy Drugs Market 2019-2023
- Published: Mar 2019
- Pages: 135
- SKU: IRTNTR31087
The 2021-2025 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
The global diabetic neuropathy drugs market size will grow by USD 866.72 million during 2019-2023. The report offers an analysis of the market based on mechanism of action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (Asia, Europe, North America, and ROW). The market research report further analyzes the market’s competitive landscape and offers information on several companies including DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Pfizer Inc.
Below are some of the key findings from the diabetic neuropathy drugs market research report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the report.
Global diabetic neuropathy drugs industry overview
Several market players in diabetic neuropathy market are increasingly focusing on the development of disease-modifying drugs for the treatment of diabetic neuropathy. The US FDA has approved tablets as a once-daily therapy for managing the neuropathic pain associated with diabetic peripheral neuropathy. Furthermore, several companies are also encouraging the development of investigational injection therapies for treating painful diabetic neuropathy. With the approval of new drugs and the presence of a strong drug pipeline, the diabetic neuropathy drugs market will register a CAGR of about 6% during the forecast period.
Moreover, the development of novel biologics for treating diabetic neuropathy in diabetic neuropathy market is one of the key trends expected to gain prominence in the market in the forthcoming years. Vendors in the diabetic neuropathy market are also focusing on developing novel biologics for treating diabetic foot ulcer, peripheral arterial disorders, and diabetic neuropathies. Companies are also focusing on launching an injectable gene therapy aimed for long-term pain relief associated with diabetic peripheral neuropathy. In addition to new drug approvals, the constant development of biologics will further boost the diabetic neuropathy drugs market growth in the forthcoming years.
Top companies covered in the diabetic neuropathy drugs market research report
The global diabetic neuropathy drugs market is moderately fragmented with companies focusing on leveraging online platforms for improving the visibility and reachability of their products. By offering a complete analysis of the market's competitive landscape and with information on the products offered by the companies, the industry analysis report will aid clients to identify new growth opportunities and design innovative strategies for strengthening their market position.
The report offers a complete analysis of various companies including:
- DAIICHI SANKYO COMPANY, LIMITED
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
Diabetic neuropathy drugs market segmentation based on geographic regions
- North America
With a complete study of the growth opportunities for companies, it has been estimated that North America will account for the highest diabetic neuropathy drugs market share throughout the forecast period. This mainly attributes to the increasing prevalence of diabetic neuropathy in the US and Canada.
Diabetic neuropathy drugs market segmentation based on mechanism of action
- Calcium channel alpha-2 delta ligand
- SNRIs and TCAs
The calcium channel alpha-2 delta ligand segment will contribute to the highest diabetic neuropathy drugs market growth as it is recommended as the first-line treatment of diabetic neuropathy. The report provides an accurate prediction of the contribution of the various mechanism of action segments to the growth of the diabetic neuropathy drugs market size.
Key highlights of the global diabetic neuropathy drugs market for the forecast years 2019-2023:
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the diabetic neuropathy drugs market during the next five years
- Precise estimation of the global diabetic neuropathy drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the industry across Asia, Europe, North America, and ROW
- A thorough analysis of the market's competitive landscape and detailed information on several vendors
- Comprehensive details on the factors that will challenge the growth of the companies
We can help! Our analysts can customize the market research report to meet your requirements. Get in touch
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.